Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Equity Average (2023 - 2025)

CG Oncology (CGON) has disclosed Equity Average for 3 consecutive years, with $720.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 13.39% year-over-year to $720.1 million, compared with a TTM value of $720.1 million through Dec 2025, up 13.39%, and an annual FY2025 reading of $743.0 million, up 143.49% over the prior year.
  • Equity Average was $720.1 million for Q4 2025 at CG Oncology, up from $679.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $720.1 million in Q4 2025 and bottomed at -$115.3 million in Q4 2023.
  • Average Equity Average over 3 years is $405.4 million, with a median of $560.6 million recorded in 2024.
  • The sharpest move saw Equity Average skyrocketed 711.04% in 2024, then grew 13.39% in 2025.
  • Year by year, Equity Average stood at -$115.3 million in 2023, then soared by 650.6% to $635.1 million in 2024, then increased by 13.39% to $720.1 million in 2025.
  • Business Quant data shows Equity Average for CGON at $720.1 million in Q4 2025, $679.0 million in Q3 2025, and $687.6 million in Q2 2025.